Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations - Report - MDSpire

Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations

  • By

  • Federica Attaianese

  • Giulia Carreras

  • Sandra Trapani

  • Ilaria Alberti

  • Maurizio Aricò

  • Marina Attanasi

  • Giulia Bertolucci

  • Silvia Bressan

  • Désirée Caselli

  • Veronica Casotto

  • Salvatore Cazzato

  • Francesco Chiarelli

  • Enrico Felici

  • Anna Frusciante

  • Maria Antonia Galeone

  • Silvia Garazzino

  • Antonietta Giannattasio

  • Eloisa Gitto

  • Antonio Guerriero

  • Fiorentina Guida

  • Giovanna Iudica

  • Marcello Lanari

  • Claudia Mandato

  • Alice Manzini

  • Gaia Martelli

  • Gregorio Paolo Milani

  • Maria Moriondo

  • Lucia Dora Notarangelo

  • Felice Nunziata

  • Roberta Pellegrino

  • Diego Peroni

  • Emanuela Piccotti

  • Eduardo Ponticiello

  • Silvia Ricci

  • Immacolata Rulli

  • Fabio Savoia

  • Erika Silvestro

  • Antonella Sisto

  • Federica Soro

  • Stefania Tonetto

  • Alessandro Zago

  • Carlo Dani

  • Chiara Azzari

  • Giuseppe Indolfi

  • July 1, 2026

  • 0 min

Share

Clinical Report: Nirsevimab Vaccination for Reducing Hospitalizations Due to RSV in Children

Overview

This study evaluates the real-world cost-effectiveness of nirsevimab in preventing RSV-associated hospitalizations across 19 Italian pediatric hospitals.

Background

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants, contributing significantly to pediatric hospital admissions globally. Preventive options have historically been limited, but nirsevimab offers a single-dose solution for all infants. Understanding the cost-effectiveness of nirsevimab in real-world settings is crucial for informing immunization strategies.

Data Highlights

No specific numerical data was provided in the source material.

Key Findings

  • Nirsevimab is a long-acting monoclonal antibody that provides seasonal protection against RSV.
  • The study analyzed data from 19 pediatric hospitals in Italy to assess the cost-effectiveness of nirsevimab.
  • Immunization campaigns varied significantly across regions in Italy, with different eligibility criteria and start dates.
  • Hospitalizations were tracked using specific ICD-9-CM codes to ensure diagnostic accuracy.
  • The cost of nirsevimab was set at €230 (US $264.50) per dose for the 2024 to 2025 season.

Clinical Implications

Variability in regional approaches to immunization highlights the need for tailored strategies.

Conclusion

The study provides insights into the cost-effectiveness of nirsevimab in preventing RSV hospitalizations.

Related Resources & Content

  1. JAMA Network Open, 2025 -- Nirsevimab and a Community Recall-Based Immunization Strategy for Child Bronchiolitis Prevention
  2. conexiant, 2025 -- Nirsevimab Linked to Lower Infant Hospitalization Risk Than Maternal Vaccine
  3. conexiant, 2025 -- RSV Prevention Tied to Lower Infant Acute Care Use
  4. Infection, 2025 -- Impact of Nirsevimab Immunization Recommendations on RSV-Related Lower Respiratory Infections in Hospitalized and Outpatient Children Under 2 in Northern Bavaria in 2024
  5. CDC, 2025 -- Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices
  6. NEJM, 2025 -- Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants
  7. PMC, 2025 -- Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis
  8. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants | New England Journal of Medicine
  9. Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis - PMC

Original Source(s)

Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations

  • by Federica Attaianese, Giulia Carreras, Sandra Trapani, Ilaria Alberti, Maurizio Aricò, Marina Attanasi, Giulia Bertolucci, Silvia Bressan, Désirée Caselli, Veronica Casotto, Salvatore Cazzato, Francesco Chiarelli, Enrico Felici, Anna Frusciante, Maria Antonia Galeone, Silvia Garazzino, Antonietta Giannattasio, Eloisa Gitto, Antonio Guerriero, Fiorentina Guida, Giovanna Iudica, Marcello Lanari, Claudia Mandato, Alice Manzini, Gaia Martelli, Gregorio Paolo Milani, Maria Moriondo, Lucia Dora Notarangelo, Felice Nunziata, Roberta Pellegrino, Diego Peroni, Emanuela Piccotti, Eduardo Ponticiello, Silvia Ricci, Immacolata Rulli, Fabio Savoia, Erika Silvestro, Antonella Sisto, Federica Soro, Stefania Tonetto, Alessandro Zago, Carlo Dani, Chiara Azzari, Giuseppe Indolfi

  • July 1, 2026

Related Content

Thoracoscopic management of easily neglected extralobar pulmonary sequestration presenting with torsion and infarction in children: three case reports and literature review

Population characteristics of children with short stature and construction of a predictive model for growth hormone treatment efficacy

Exploring the paradox between perception and actual childhood drowning risk: an evidence-based study in Bangladesh